Publisher Correction: Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma

Decraene, Brecht; Yang, Yihan; Smet, Frederik De; Garg, Abhishek D.; Agostinis, Patrizia; Vleeschouwer, Steven De

doi:10.1038/s41435-022-00187-3

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The interaction between DAMPs and the immune system transforms the tumor microenvironment from an immunologically "cold" state to an immunogenic "hot" state, promoting anti-tumor immune responses [8,9]. Given the stressor-dependent nature of ICD induction, various strategies have been employed to design small molecules, metallic compounds, or nano-platforms to induce ICD by eliciting stress in cancer cells [10][11][12]. Targeting mitochondria to trigger reactive oxygen species (ROS) generation has emerged as a promising approach to induce ICD, highlighting the importance of mitochondrial ROS in amplifying anti-tumor immune responses [13][14][15].…”

Section: Introductionmentioning

confidence: 99%

The Conjugate of Rhein–Artesunate for Inducing Immunogenic Cell Death to Prepare Cancer Vaccine and Suppress Tumor Growth

Xu,

Wang,

Huang

2024

Chemistry

View full text Add to dashboard Cite

The conjugate of rhein and artesunate have shown promising effects in inducing immunogenic cell death (ICD) and inhibiting tumor growth. Rhein, a natural anthraquinone derivative found in various medicinal plants such as Rheum palmatum, possesses diverse pharmacological properties including anti-inflammatory and anticancer activities. Artesunate, a sesquiterpene lactone extracted from Artemisia annua, exhibits potent antimalarial efficacy and has garnered attention for its potential anticancer properties. Through rational drug design, the conjugation of rhein with artesunate has yielded compounds capable of selectively targeting mitochondria of cancer cells, inducing oxidative stress-mediated ICD, and enhancing the immunogenicity of tumor cells. The conjugate leverages the inherent cytotoxicity of artesunate while incorporating the capability to selectively target the mitochondria of rhein, thereby fostering a special approach to immunotherapy for cancer. Upon accumulation in the mitochondria, these compounds induce the generation of reactive oxygen species (ROS), leading to mitochondrial membrane potential (ΔΨm) reduction and endoplasmic reticulum (ER) stress. Notably, the conjugate exhibits far more potent ICD-inducing properties than their parent compounds. In vivo studies have demonstrated that the vaccine, when treated with the conjugate, effectively suppresses tumor growth.

show abstract